|
Valneva Se (NASDAQ: VALN) |
|
Valneva Se
VALN's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Valneva Se's sales fell
by -57.46 % in IV. Quarter 2023 from the same quarter a year ago.
Ranking at No. 1245
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -1.86 %
Valneva Se net loss decreased from $-160 millions, to $-114 millions in IV. Quarter 2023,
• More on VALN's Growth
|
|
Valneva Se realized a net loss in trailing twelve months.
Valneva Se realized cash reduction of $ 0 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 6.72.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.69.
• More on VALN's Valuation
|
|
|
|
|
Valneva Se realized net loss in trailing twelve months.
Valneva Se realized cash outflow of $ 0per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 6.72.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.69.
Valneva Se Price to Book Ratio is at 8.06 higher than Industry Avg. of -0, and higher than S&P 500 Avg. of 0.02
• More on VALN's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com